IP Library Granted Patent US 9,434,702
Granted Patent B2
US 9,434,702 · App. 14/378,825 · Granted Sep 6, 2016

Method for preparing linezolid intermediate

Inventors: Fuli Zhang (Shangai, CN); Chunbo Yang (Shangai, CN); Bin Liang (Shangai, CN); Pengcheng Qiu (Shangai, CN); Hairong Luo (Zhejiang, CN); Jiang Li (Zhejiang, CN); Jian Chai (Zhejiang, CN); Qingfeng Cai (Zhejiang, CN)
Assignees: Zhejiang Hisun Pharamceutical Co., Ltd.; Shanghai Institute of Pharmaceutical Industry
C07D263/20C07D413/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,434,702
App. No.
14/378,825
Granted
Sep 6, 2016
Kind
B2
Abstract

Disclosed is a new method for preparing a methyl substitute of a linezolid intermediate, (S)-2-(3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazoline) (I), wherein the intermediate (I) is obtained by the cyclization of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III). This process has a short process route, low cost, easy operation, and high yield, so is suitable for a large-scale industrial production.

Claims (15)

1. A process for preparing an intermediate of Linezolid of Formula (I):

the process comprises the following steps:

a cyclization reaction of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III) is performed to obtain the compound of Formula (I),

wherein R is a protected amino group as follows:

2. The process according to claim 1 , wherein the cyclization reaction is performed in the presence of a catalyst, preferably, the catalyst is a Lewis acid or a mixture thereof.

3. The process according to claim 2 , wherein the catalyst is selected from lithium bromide, magnesium bromide, lithium chloride, magnesium chloride, magnesium iodide, lithium iodide, lithium chloride, zinc chloride, tetra-n-butylammonium bromide, tetra-n-butylammonium chloride, or any mixture thereof.

4. The process according to claim 2 , wherein the catalyst is selected from lithium bromide, magnesium bromide, magnesium iodide, or any mixture thereof.

5. The process according to claim 1 , wherein the cyclization reaction is performed in a solvent, preferably, the solvent is an aprotic solvent or a mixture thereof.

6. The process according to claim 5 , wherein the aprotic solvent includes but not limited to petroleum ether, ethyl acetate, isoamyl acetate, butyl acetate, toluene, xylene, chlorobenzene, tetrahydrofuran, dichloromethane, N, N-dimethylformamide, C 6 -C 8 alkanes, acetone, 1,4-dioxane, acetonitrile, or any mixture thereof.

7. The process according to claim 1 , wherein the temperature of the cyclization reaction is in the range of 60° C.-150° C.

8. The process according to claim 7 , wherein the temperature of the cyclization reaction is in the range of 100-140° C., particularly preferably 115-125° C.

9. A process for preparing linezolid, wherein linezolid is prepared from the intermediate of Formula (I)

wherein the intermediate of Formula (I) is prepared by the reaction as follows:

a cyclization reaction of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III) is performed to obtain the compound of Formula (I), wherein R is a protected amino group as follows:

followed by deprotection and acetylation to obtain linezolid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2014
From: ZHANG, FULI; YANG, CHUNBO; LIANG, BIN; QIU, PENGCHENG; LUO, HAIRONG; LI, JIANG; CHAI, JIAN; CAI, QINGFENG
To: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
Reel/Frame 033650/0111 →
Priority Claims (1)
CN 2012 1 0038198.3 · Feb 15, 2012 · national
Continuity (1)
Related Publication 20150011757A1 · Jan 8, 2015